Results 11 to 20 of about 8,086 (190)

EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer [PDF]

Nature Communications, 2021
Although the TMPRSS2-ERG gene fusion is the most common alteration in human prostate cancer, its involvement in disease progression remains unclear. Here, the authors demonstrate that ERG is methylated by Enhancer of zest homolog 2 leading to enhanced ...
Marita Zoma, Laura Curti, Dheeraj Shinde, Domenico Albino, Abhishek Mitra, Jacopo Sgrignani, Sarah N. Mapelli, Giada Sandrini, Gianluca Civenni, Jessica Merulla, Giovanna Chiorino, Paolo Kunderfranco, Alessia Cacciatore, Aleksandra Kokanovic, Andrea Rinaldi, Andrea Cavalli, Carlo V. Catapano, Giuseppina M. Carbone   +17 more
doaj   +2 more sources

Detection of TMPRSS2 : ERG fusion gene in circulating prostate cancer cells [PDF]

Asian Journal of Andrology, 2008
Creative Commons Attribution-NonCommercial-Share Alike 3.0 license (CC BY-NC SA)Aim: To investigate the existence of TMPRSS2:ERG fusion gene in circulating tumor cells (CTC) from prostate cancer patients and its potential in monitoring tumor metastasis ...
Bryan D. Young, Dan Berney, David M. Prowse, Greg Shaw, Jemal A, Lin B, Patricia Purkis, Pelkey TJ, R. Tim D. Oliver, Sakunthala C. Kudahetti, Saname Kia, Sharon Y. James, Theodora Tsigani, Ulbright TM., Winnes M, Xueying Mao, Yong-Jie Lu   +16 more
core   +3 more sources

Identification of novel somatic fusions of ERG‐VEGFA, TMPRSS2‐ERG, and VEGFA‐TMPRSS2 in prostate cancer treated with anlotinib and androgen deprivation therapy: A case report [PDF]

Cancer Innovation, 2022
The TMPRSS2‐ERG fusion gene has frequently been found in prostate cancer and is associated with malignancy. Identifying novel fusions will help to stratify patients and establish patient‐tailored therapies.
Qiuli Liu, Shuo Wang, Ze Wang, Peng Tang, Dianzheng Zhang, Weihua Lan, Jun Jiang   +6 more
doaj   +2 more sources

Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer

Neoplasia: An International Journal for Oncology Research, 2008
TMPRSS2-ERG gene fusions are the predominant molecular subtype of prostate cancer. Here, we explored the role of TMPRSS2-ERG gene fusion product using in vitro and in vivo model systems.
Scott A. Tomlins, Bharathi Laxman, Sooryanarayana Varambally, Xuhong Cao, Jindan Yu, Beth E. Helgeson, Qi Cao, John R. Prensner, Mark A. Rubin, Rajal B. Shah, Rohit Mehra, Arul M. Chinnaiyan   +11 more
doaj   +3 more sources

TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model [PDF]

BMC Cancer, 2019
Background Castrate Resistant Prostate Cancer (CRPC) is an advanced disease resistant to systemic traditional medical or surgical castration, and resistance is primarily attributed to reactivation of AR through multiple mechanisms.
Louie Semaan, Navneet Mander, Michael L. Cher, Sreenivasa R. Chinni   +3 more
doaj   +2 more sources

Transcriptomes of Prostate Cancer with TMPRSS2:ERG and Other ETS Fusions. [PDF]

Mol Cancer Res, 2023
Abstract The most common somatic event in primary prostate cancer is a fusion between the androgen-related TMPRSS2 gene and the ERG oncogene. Tumors with these fusions, which occur early in carcinogenesis, have a distinctive etiology.
Stopsack KH, Su XA, Vaselkiv JB, Graff RE, Ebot EM, Pettersson A, Lis RT, Fiorentino M, Loda M, Penney KL, Lotan TL, Mucci LA.   +11 more
europepmc   +6 more sources

Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer. [PDF]

PLoS ONE, 2015
TMPRSS2-ERG junction oncogene is present in more than 50% of patients with prostate cancer and its expression is frequently associated with poor prognosis.
Giorgia Urbinati, Hafiz Muhammad Ali, Quentin Rousseau, Hubert Chapuis, Didier Desmaële, Patrick Couvreur, Liliane Massaad-Massade   +6 more
doaj   +1 more source

TMPRSS2-ERG gene fusion in prostate cancer [PDF]

Biomedical Papers, 2014
The TMPRSS2-ERG gene fusion is one of the most widely spread chromosomal rearrangements in carcinomas. Since its discovery, a number of studies have examined its diagnostic, prognostic and therapeutic implications for prostate cancer where suitable biomarkers are still lacking. The publication data are inconsistent.
Alena, Burdova, Jan, Bouchal, Spiros, Tavandzis, Zdenek, Kolar   +3 more
openaire   +2 more sources

TMPRSS2- driven ERG expression in vivo increases self-renewal and maintains expression in a castration resistant subpopulation. [PDF]

PLoS ONE, 2012
Genomic rearrangements commonly occur in many types of cancers and often initiate or alter the progression of disease. Here we describe an in vivo mouse model that recapitulates the most frequent rearrangement in prostate cancer, the fusion of the ...
Orla M Casey, Lei Fang, Paul G Hynes, Wassim G Abou-Kheir, Philip L Martin, Heather S Tillman, Gyorgy Petrovics, Hibah O Awwad, Yvona Ward, Ross Lake, Luhua Zhang, Kathleen Kelly   +11 more
doaj   +1 more source

Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer. [PDF]

Dis Markers, 2019
There is increasing interest in the use of cell-free circulating tumor DNA (ctDNA) as a serum marker for therapy assessment in prostate cancer patients. Prostate cancer is characterized by relatively low numbers of mutations, and, in contrast to many other common epithelial cancers, commercially available single nucleotide mutation assays for ...
Krumbholz M, Agaimy A, Stoehr R, Burger M, Wach S, Taubert H, Wullich B, Hartmann A, Metzler M.   +8 more
europepmc   +3 more sources